Mesoblast (MESO): Net earnings per share growth forecast for next year

Corporate emblem and logo of mesoblast.com (MESO)

Mesoblast Limited (MESO) generates revenue through the commercialization of cell-based products designed to treat cardiovascular pathologies. This chart of the consensus EPS n+1 forecast reflects market expectations, where the value 261.10 describes the current level. Production is partially automated, although the clinical stage requires expert oversight. The R&D cycle is currently completing the regulatory approval stage to bring breakthrough therapies to market.

Mesoblast Ltd (MESO): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Mesoblast (MESO)

- share price and consensus valuation forecast:
Stock Price Mesoblast Ltd|MESO - Average Forecast Price
- stock exchange capitalization data:
Market Value Mesoblast Pharma|MESO - Company Buyout Price
- company book value details:
Net Assets per Single Share Mesoblast|MESO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio mesoblast.com|MESO - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Mesoblast Limited|MESO - Long-Term Debt to Equity|Short-Term Debt to Capital Mesoblast Ltd|MESO - Company Aggregate Debts|Debt to Book Capitalization Ratio Mesoblast Pharma|MESO - Long-Term Debt Volume|Company Current Liabilities Mesoblast|Quick Liquidity Indicator mesoblast.com
- net income and valuation ratios data:
MESO - Final Profit|Expected Profit Mesoblast Limited|MESO - Price to Earnings Ratio|Forward P/E Multiple Mesoblast Ltd|MESO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesoblast Corp|MESO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Mesoblast|MESO - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months mesoblast.com|MESO - Net earnings per one share growth for the current year|Earnings growth forecast for next year Mesoblast Limited
- total revenue and sales volume data:
MESO - Company Total Revenue|Projected Sales Volume Mesoblast|MESO - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio Mesoblast Corp
Basic company analysis:MESO, mesoblast.com
Core merchandise of mesoblast.com

Mesoblast Limited (MESO) achievements in cell therapy and partnerships with pharmaceutical behemoths determine future capitalization based on clinical trial results. The price action of the annual EPS growth for the next period reflects analysts' daily profit re-evaluations, where sharp fluctuations in the indicator signal rising business uncertainty, warning investors of potential risks of a deep asset drawdown.

Competitor analysis

LCTX (lineagecell.com) - Earnings growth forecast for next year|Earnings growth forecast for next year surrozen.com|Expected earnings per share growth for next year CCEL (Cryo-Cell International)|Net earnings per share growth forecast for next year FBLG (FibroBiologics Inc.)|Earnings growth forecast for next year LGVN (Longeveron Inc)|Expected earnings per share trend next year BRTX|CELZ: Expected earnings per share growth for next year